| dc.contributor.author | Thomas, Lance R. | |
| dc.contributor.author | Adams, Clare M. | |
| dc.contributor.author | Fesik, Stephen W. | |
| dc.contributor.author | Eischen, Christine M. | |
| dc.contributor.author | Tansey, William P. | |
| dc.date.accessioned | 2020-09-04T16:49:33Z | |
| dc.date.available | 2020-09-04T16:49:33Z | |
| dc.date.issued | 2020-03-03 | |
| dc.identifier.citation | Lance R. Thomas, Clare M. Adams, Stephen W. Fesik, Christine M. Eischen & William P. Tansey (2020) Targeting MYC through WDR5, Molecular & Cellular Oncology, 7:2, 1709388, DOI: 10.1080/23723556.2019.1709388 | en_US |
| dc.identifier.other | eISSN: 2372-3556 | |
| dc.identifier.uri | http://hdl.handle.net/1803/15598 | |
| dc.description.abstract | The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated - but currently undruggable - anti-cancer target. We recently showed that breaking the interaction of MYC with its chromatin co-factor WD repeat-containing protein 5 (WDR5) promotes tumor regression in mouse xenografts, laying the foundation for a new strategy to inhibit MYC in the clinic. | en_US |
| dc.description.sponsorship | This project has been funded in part with Federal funds from the National Cancer Institute, under Chemical Biology Consortium Contract No. HHSN261200800001E and grants CA200709, CA211305, CA148950, CA056036, and CA68485. This work was also supported by grants from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, The TJ Martell Foundation, St. Baldrick's Foundation, Alex's Lemonade Stand Foundation, and the Edward P. Evans Foundation. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | Molecular & Cellular Oncology | en_US |
| dc.rights | © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. | |
| dc.source.uri | https://www.tandfonline.com/doi/full/10.1080/23723556.2019.1709388?scroll=top&needAccess=true | |
| dc.subject | Cancer | en_US |
| dc.subject | MYC | en_US |
| dc.subject | WDR5 | en_US |
| dc.subject | Cancer therapy | en_US |
| dc.title | Targeting MYC through WDR5 | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1080/23723556.2019.1709388 | |
